trending Market Intelligence /marketintelligence/en/news-insights/trending/TJjLhEtd66qrs8PpwyUJQg2 content esgSubNav
In This List

Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

Calithera BioSciences Inc. is partnering with Bristol-Myers Squibb Co. to determine whether its CB-839 drug can be combined with Opdivo to treat kidney cancer.

Bristol-Myers' Opdivo is already approved as a treatment for certain types of cancer. CB-839 is currently in phase 1/2 clinical studies involving patients with clear cell renal cell carcinoma.